Olyos Group has acquired a controlling stake in NewScience
December 2025 — Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Olyos, headquartered in France, has been controlled since 2023 by European private equity firm Motion Equity Partners. With over 75 years of history, Olyos is an international nutrition and health platform, generating US$150 million (€130 million) in annual revenues. Olyos’ strategy is based on a combination of organic and inorganic growth across its brands, supported by a scientific and pharmaceutical-driven approach. To date, the group has completed seven strategic acquisitions to expand its geographic footprint.
Founded over 15 years ago by Juan Pablo Salas, NewScience is a well-established company in the nutritional supplements market, with a strong presence across categories such as omega-3, probiotics, specialized magnesium, collagen, vitamins and minerals. The company is the market leader in omega-3 supplements. NewScience operates a fully integrated, asset-light business model, outsourcing manufacturing, packaging and quality control, while focusing on R&D, top-tier suppliers and a strong commercial strategy. This approach has enabled the company to establish a presence in more than 1,700 points of sale, as well as digital channels. NewScience has nationwide coverage in Chile, operations in Ecuador and international expansion plans currently underway.
Our role in the transaction
Oaklins’ team in Chile acted as the exclusive buy-side financial advisor to Olyos in the acquisition of a controlling stake in NewScience S.A. It provided strategic and financial advice throughout the transaction, including valuation analysis, transaction structuring and negotiations with the sellers. Oaklins’ French team supported the early stages of the transaction, including the introduction that led to the mandate and the initial connection with Olyos.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more